ArticlePharmaceuticals (Basel, Switzerland)2026

Ocrelizumab-Induced Brain Volume Dynamics in Relapsing-Remitting Multiple Sclerosis.

Roberto De Masi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.